Preclinical data demonstrated that TIM-3 blockade is effective not only in counter-modulating dysfunctional CD8+ T cells and Tregs but also in restoring NK cytotoxic activity and TNF-alpha and IFN-γ production in lung cancer (83). The gene discussed is HAVCR2; the disease is lung cancer.